These data well align with in vitro and in vivo studies indicating a main contribution of the EGFR/GPER-mediated signaling pathway in pro-tumorigenic features as well as drug resistance in BC cells [10, 18, 112, 113]. This evidence concerns the gene EGFR and breast cancer.